These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 3894280)

  • 21. Efficacy of fludarabine, intermittent sequential high-dose cytosine arabinoside, and mitoxantrone (FIS-HAM) salvage therapy in highly resistant acute leukemias.
    Kern W; Schleyer E; Braess J; Wittmer E; Ohnesorge J; Unterhalt M; Wörmann B; Büchner T; Hiddemann W
    Ann Hematol; 2001 Jun; 80(6):334-9. PubMed ID: 11475146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
    Kimby E; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia.
    De La Serna J; Francisco Tomás J; Solano C; García de Paredes ML; Campbell J; Grande C; Diaz-Mediavilla J
    Leuk Lymphoma; 1997 Apr; 25(3-4):365-72. PubMed ID: 9168446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitoxantrone and continuous infusion of cytosine arabinoside in refractory and relapsed acute lymphoblastic leukemia.
    Liso V; Specchia G; Capalbo S; Pavone V; Iacobazzi A; Iaculli ML; Dione R; Pansini N
    Acta Haematol; 1992; 87(1-2):54-7. PubMed ID: 1585771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
    Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
    Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
    J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM).
    Hiddemann W; Büchner T; Heil G; Schumacher K; Diedrich H; Maschmeyer G; Ho AD; Planker M; Gerith-Stolzenburg S; Donhuijsen-Ant R
    Leukemia; 1990 Sep; 4(9):637-40. PubMed ID: 2395383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
    Sampi K; Ogawa M; Kimura I; Ohnoshi T; Yamada K; Masaoka T; Wakui A; Meguro S; Nagai K; Kitani T
    Gan To Kagaku Ryoho; 1986 Oct; 13(10):3021-7. PubMed ID: 3464230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients.
    Lejeune C; Tubiana N; Gastaut JA; Maraninchi D; Richard B; Launay MC; Sainty D; Sebahoun G; Carcassonne Y
    Eur J Haematol; 1990 Apr; 44(4):240-3. PubMed ID: 2344886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Phase II study of mitoxantrone in patients with acute leukemia].
    Kimura K; Yoshikawa S; Yoshikawa H; Yamada K; Hirano M; Ikeda Y; Ohta K; Ohara K; Kobayashi M; Shirakawa S
    Gan To Kagaku Ryoho; 1986 Aug; 13(8):2573-80. PubMed ID: 3740858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Mitoxantrone and conventional-dose cytosine arabinoside for relapsed and refractory acute leukemia].
    Wakita A; Murase T; Uchida T; Fujiwara Y; Tanaka M; Ohkita T
    Gan To Kagaku Ryoho; 1992 May; 19(5):653-7. PubMed ID: 1580638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia.
    Thomas X; Cambier N; Taksin AL; Reman O; Vekhoff A; Pautas C; Leblond V; Soler-Michel P; Ecstein-Fraïssé E; Archimbaud E
    Leuk Res; 2000 Nov; 24(11):957-63. PubMed ID: 11086179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study.
    Karanes C; Kopecky KJ; Head DR; Grever MR; Hynes HE; Kraut EH; Vial RH; Lichtin A; Nand S; Samlowski WE; Appelbaum FR
    Leuk Res; 1999 Sep; 23(9):787-94. PubMed ID: 10475617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An EORTC phase II study of mitoxantrone in solid tumors and lymphomas.
    De Jager R; Cappelaere P; Armand JP; Keiling R; Fargeot P; Bastit P; van Glabbeke M; Renard J; Earl H; Rubens R
    Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1369-75. PubMed ID: 6542006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
    Wrzesień-Kuś A; Robak T; Wierzbowska A; Lech-Marańda E; Pluta A; Wawrzyniak E; Krawczyńska A; Kuliczkowski K; Mazur G; Kiebiński M; Dmoszyńska A; Wach M; Hellmann A; Baran W; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S;
    Ann Hematol; 2005 Sep; 84(9):557-64. PubMed ID: 15856358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of refractory or relapsed adult acute leukemia by using mitoxantrone-containing regimens.
    Lin MT; Chen YC; Liu TW; Tien HF; Liu MC; Wang CH; Shen MC; Liu CH
    Taiwan Yi Xue Hui Za Zhi; 1989; 88(11-12):1116-22. PubMed ID: 2636248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
    Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):73-7. PubMed ID: 3473685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
    Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M
    J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas].
    Kimura I; Ohnoshi T; Ogawa M; Sampi K; Masaoka T; Yamada K; Ohta K; Kitani T; Kawagoe H; Shirakawa S
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2800-6. PubMed ID: 3753026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.
    Bassan R; Lerede T; Buelli M; Borleri G; Bellavita P; Rambaldi A; Barbui T
    Haematologica; 1998 May; 83(5):422-7. PubMed ID: 9658726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.